Key result
Long-term use (3 years or more) of imatinib, as monotherapy or in combination with bosentan, was reported in two cases of pulmonary arterial hypertension.
Why the study?
Does long-term imatinib treatment improve outcomes in patients with pulmonary arterial hypertension?
Population
2 patients with pulmonary arterial hypertension (PAH)
Design
Case_series
Follow-up
3 years or more
Authors
Loading...
Short-term imatinib addition may extend options in refractory PAH; leaves open efficacy and safety pending randomized data.
Case Report (n=2)
Does long-term imatinib treatment improve outcomes in patients with pulmonary arterial hypertension?
This report describes the first two cases of long-term imatinib use (3 years or more) for the treatment of pulmonary arterial hypertension.
Rogério Souza (2006) conducted a case report in Pulmonary arterial hypertension (n=2). Imatinib was evaluated. Long-term use (3 years or more) of imatinib, as monotherapy or in combination with bosentan, was reported in two cases of pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: